2366

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

FORM FD-1572 (8/64)	STATEMENT OF INVESTIGATOR (Clinical Pharmacology)
DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE FOOD AND DRUG ADMINISTRATION	
TO SUPPLIER OF THE DRUG (Name and Address)	NAME OF INVESTIGATOR (Print or Type)
	DATE
	NAME OF DRUG
Dear Sir: The undersigned,	
submits this statement as required by section 505(i) of the F	ederal Food, Drug, and Cosmetic Act and \$130.3 of Title 21 of the Cocucting clinical pharmacology with a new drug limited by Federal (or
1. A STATEMENT OF THE EDUCATION AND TRAINING THAT Q	QUALIFIES ME FOR CLINICAL PHARMACOLOGY.
THE NAME AND ADDRESS OF THE MEDICAL SCHOOL, HOSP PHARMACOLOGY WILL BE CONDUCTED.	PITAL, OR OTHER RESEARCH FACILITY WHERE THE CLINICAL
3. THE EXPERT COMMITTEES OR PANELS RESPONSIBLE FOR	R APPROVING THE EXPERIMENTAL PROJECT;
4. THE ESTIMATED DURATION OF THE PROJECT, AND THE N	MAXIMUM NUMBER OF SUBJECTS THAT WILL BE INVOLVED:
5. A GENERAL OUTLINE OF THE PROJECT TO BE UNDERTAIN advance submission of amendments to the general outline.)	KEN. (Modification is permitted on the basis of experience gained without